{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:54:56Z","timestamp":1794567296729,"version":"4.9.1"},"publisher-location":"New York, NY","reference-count":108,"publisher":"Springer New York","isbn-type":[{"value":"9781493978243","type":"print"},{"value":"9781493978250","type":"electronic"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1007\/978-1-4939-7825-0_14","type":"book-chapter","created":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T08:44:16Z","timestamp":1527756256000},"page":"267-284","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Nonhuman Primate Models of Huntington\u2019s Disease and Their Application in Translational Research"],"prefix":"10.1007","author":[{"given":"Romina","family":"Aron Badin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,1]]},"reference":[{"key":"14_CR1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/ng0893-387","volume":"4","author":"M Duyao","year":"1993","unstructured":"Duyao M, Ambrose C, Myers R et al (1993) Trinucleotide repeat length instability and age of onset in Huntington\u2019s disease. Nat Genet 4:387\u2013392","journal-title":"Nat Genet"},{"key":"14_CR2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"The Huntington\u2019s Disease Collaborative Research Group","year":"1993","unstructured":"The Huntington\u2019s Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell 72:971\u2013983","journal-title":"Cell"},{"key":"14_CR3","doi-asserted-by":"crossref","first-page":"5196","DOI":"10.1128\/MCB.00079-08","volume":"28","author":"J Shao","year":"2008","unstructured":"Shao J, Welch WJ, Diprospero NA, Diamond MI (2008) Phosphorylation of profilin by ROCK1 regulates polyglutamine aggregation. Mol Cell Biol 28:5196\u20135208","journal-title":"Mol Cell Biol"},{"key":"14_CR4","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0962-8924(00)01853-5","volume":"10","author":"AJ Tobin","year":"2000","unstructured":"Tobin AJ, Signer ER (2000) Huntington\u2019s disease: the challenge for cell biologists. Trends Cell Biol 10:531\u2013536","journal-title":"Trends Cell Biol"},{"key":"14_CR5","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/nrn1806","volume":"6","author":"E Cattaneo","year":"2005","unstructured":"Cattaneo E, Zuccato C, Tartari M (2005) Normal huntingtin function: an alternative approach to Huntington\u2019s disease. Nat Rev Neurosci 6:919\u2013930","journal-title":"Nat Rev Neurosci"},{"key":"14_CR6","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","volume":"44","author":"JP Vonsattel","year":"1985","unstructured":"Vonsattel JP, Myers RH, Stevens TJ et al (1985) Neuropathological classification of Huntington\u2019s disease. J Neuropathol Exp Neurol 44:559\u2013577","journal-title":"J Neuropathol Exp Neurol"},{"issue":"4725","key":"14_CR7","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1126\/science.2931802","volume":"230","author":"RJ Ferrante","year":"1985","unstructured":"Ferrante RJ, Kowall NW, Beal MF et al (1985) Selective sparing of a class of striatal neurons in Huntington\u2019s disease. Science 230(4725):561\u2013563","journal-title":"Science"},{"key":"14_CR8","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0006-8993(87)90694-9","volume":"411","author":"RJ Ferrante","year":"1987","unstructured":"Ferrante RJ, Beal MF, Kowall NW et al (1987) Sparing of acetylcholinesterase-containing striatal neurons in Huntington\u2019s disease. Brain Res 411:162\u2013166","journal-title":"Brain Res"},{"key":"14_CR9","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/0167-0115(93)90028-7","volume":"46","author":"NW Kowall","year":"1993","unstructured":"Kowall NW, Quigley BJ Jr, Krause JE et al (1993) Substance P and substance P receptor histochemistry in human neurodegenerative diseases. Regul Pept 46:174\u2013185","journal-title":"Regul Pept"},{"issue":"1\u20132","key":"14_CR10","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0165-0173(00)00039-4","volume":"34","author":"F Cicchetti","year":"2000","unstructured":"Cicchetti F, Prensa L, Wu Y, Parent A (2000) Chemical anatomy of striatal interneurons in normal individuals and in patients with Huntington\u2019s disease. Brain Res Rev 34(1\u20132):80\u2013101","journal-title":"Brain Res Rev"},{"issue":"2","key":"14_CR11","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1055\/s-2007-971176","volume":"27","author":"FO Walker","year":"2007","unstructured":"Walker FO (2007) Huntington\u2019s disease. Semin Neurol 27(2):143\u2013150","journal-title":"Semin Neurol"},{"key":"14_CR12","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/brain\/119.5.1633","volume":"119","author":"AD Lawrence","year":"1996","unstructured":"Lawrence AD, Sahakian BJ, Hodges JR et al (1996) Executive and mnemonic functions in early Huntington\u2019s disease. Brain 119:1633\u20131645","journal-title":"Brain"},{"key":"14_CR13","first-page":"179","volume":"65","author":"JL Cummings","year":"1995","unstructured":"Cummings JL (1995) Behavioral and psychiatric symptoms associated with Huntington\u2019s disease. Adv Neurol 65:179\u2013186","journal-title":"Adv Neurol"},{"key":"14_CR14","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.biopsych.2006.11.034","volume":"62","author":"K Duff","year":"2007","unstructured":"Duff K, Paulsen JS, Beglinger LJ et al (2007) Psychiatric symptoms in Huntington\u2019s disease before diagnosis: the predict-HD study. Biol Psychiatry 62:1341\u20131346","journal-title":"Biol Psychiatry"},{"key":"14_CR15","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/archneur.64.1.116","volume":"64","author":"J Marshall","year":"2007","unstructured":"Marshall J, White K, Weaver M et al (2007) Specific psychiatric manifestations among preclinical Huntington disease mutation carriers. Arch Neurol 64:116\u2013121","journal-title":"Arch Neurol"},{"key":"14_CR16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1176\/jnp.15.1.109","volume":"15","author":"G Huntington","year":"2003","unstructured":"Huntington G (2003) On chorea. George Huntington, M.D. J Neuropsychiatry Clin Neurosci 15:109\u2013112","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"14_CR17","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1212\/WNL.36.2.244","volume":"36","author":"AB Young","year":"1986","unstructured":"Young AB, Shoulson I, Penney JB et al (1986) Huntington\u2019s disease in Venezuela: neurologic features and functional decline. Neurology 36:244\u2013249","journal-title":"Neurology"},{"key":"14_CR18","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/ilar.48.4.356","volume":"48","author":"S Ramaswamy","year":"2007","unstructured":"Ramaswamy S, McBride JL, Kordower JH (2007) Animal models of Huntington\u2019s disease. ILAR J 48:356\u2013373","journal-title":"ILAR J"},{"key":"14_CR19","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nrn3570","volume":"14","author":"MA Pouladi","year":"2013","unstructured":"Pouladi MA, Morton AJ, Hayden MR (2013) Choosing an animal model for the study of Huntington\u2019s disease. Nat Rev Neurosci 14:708\u2013721","journal-title":"Nat Rev Neurosci"},{"key":"14_CR20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0014-4886(90)90014-J","volume":"108","author":"P Hantraye","year":"1990","unstructured":"Hantraye P, Riche D, Maziere M, Isacson O (1990) A primate model of Huntington\u2019s disease: behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon. Exp Neurol 108:91\u2013104","journal-title":"Exp Neurol"},{"key":"14_CR21","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0304-3940(86)90566-5","volume":"71","author":"I Kanazawa","year":"1986","unstructured":"Kanazawa I, Tanaka Y, Cho F (1986) \u2018Choreic\u2019 movement induced by unilateral kainate lesion of the striatum and L-DOPA administration in monkey. Neurosci Lett 71:241\u2013246","journal-title":"Neurosci Lett"},{"key":"14_CR22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0022-510X(85)90084-X","volume":"70","author":"I Kanazawa","year":"1985","unstructured":"Kanazawa I, Sasaki H, Muramoto O et al (1985) Studies on neurotransmitter markers and striatal neuronal cell density in Huntington\u2019s disease and dentatorubropallidoluysian atrophy. J Neurol Sci 70:151\u2013165","journal-title":"J Neurol Sci"},{"key":"14_CR23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1006\/exnr.1993.1006","volume":"119","author":"RJ Ferrante","year":"1993","unstructured":"Ferrante RJ, Kowall NW, Cipolloni PB et al (1993) Excitotoxin lesions in primates as a model for Huntington\u2019s disease: histopathologic and neurochemical characterization. Exp Neurol 119:46\u201371","journal-title":"Exp Neurol"},{"key":"14_CR24","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/0306-4522(94)00431-4","volume":"64","author":"LH Burns","year":"1995","unstructured":"Burns LH, Pakzaban P, Deacon TW et al (1995) Selective putaminal excitotoxic lesions in non-human primates model the movement disorder of Huntington disease. Neuroscience 64:1007\u20131017","journal-title":"Neuroscience"},{"key":"14_CR25","first-page":"137","volume":"50","author":"BZ Roitberg","year":"2002","unstructured":"Roitberg BZ, Emborg ME, Sramek JG et al (2002) Behavioral and morphological comparison of two nonhuman primate models of Huntington\u2019s disease. Neurosurgery 50:137\u2013145. discussion 145\u2013146","journal-title":"Neurosurgery"},{"key":"14_CR26","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/0166-2236(90)90111-M","volume":"13","author":"M DiFiglia","year":"1990","unstructured":"DiFiglia M (1990) Excitotoxic injury of the neostriatum: a model for Huntington\u2019s disease. Trends Neurosci 13:286\u2013289","journal-title":"Trends Neurosci"},{"key":"14_CR27","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1177\/096368979200100409","volume":"1","author":"JM Schumacher","year":"1992","unstructured":"Schumacher JM, Hantraye P, Brownell AL et al (1992) A primate model of Huntington\u2019s disease: functional neural transplantation and CT-guided stereotactic procedures. Cell Transplant 1:313\u2013322","journal-title":"Cell Transplant"},{"key":"14_CR28","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/brain\/123.7.1442","volume":"123","author":"AL Kendall","year":"2000","unstructured":"Kendall AL, David F, Rayment G et al (2000) The influence of excitotoxic basal ganglia lesions on motor performance in the common marmoset. Brain 123:1442\u20131458","journal-title":"Brain"},{"key":"14_CR29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1006\/exnr.1994.1004","volume":"125","author":"AL Brownell","year":"1994","unstructured":"Brownell AL, Hantraye P, Wullner U et al (1994) PET- and MRI-based assessment of glucose utilization, dopamine receptor binding, and hemodynamic changes after lesions to the caudate-putamen in primates. Exp Neurol 125:41\u201351","journal-title":"Exp Neurol"},{"key":"14_CR30","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/ana.410240417","volume":"24","author":"R Schwarcz","year":"1988","unstructured":"Schwarcz R, Tamminga CA, Kurlan R, Shoulson I (1988) Cerebrospinal fluid levels of quinolinic acid in Huntington\u2019s disease and schizophrenia. Ann Neurol 24:580\u2013582. https:\/\/doi.org\/10.1002\/ana.410240417","journal-title":"Ann Neurol"},{"key":"14_CR31","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fnins.2014.00012","volume":"8","author":"BM Campbell","year":"2014","unstructured":"Campbell BM, Charych E, Lee AW, Moller T (2014) Kynurenines in CNS disease: regulation by inflammatory cytokines. Front Neurosci 8:12. https:\/\/doi.org\/10.3389\/fnins.2014.00012","journal-title":"Front Neurosci"},{"issue":"6066","key":"14_CR32","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/321168a0","volume":"321","author":"MF Beal","year":"1986","unstructured":"Beal MF, Kowall NW, Ellison DW et al (1986) Replication of the neurochemical characteristics of Huntington\u2019s disease by quinolinic acid. Nature 321(6066):168\u2013171","journal-title":"Nature"},{"key":"14_CR33","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s00702-004-0201-4","volume":"111","author":"G Gardian","year":"2004","unstructured":"Gardian G, Vecsei L (2004) Huntington\u2019s disease: pathomechanism and therapeutic perspectives. J Neural Transm (Vienna) 111:1485\u20131494","journal-title":"J Neural Transm (Vienna)"},{"key":"14_CR34","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0301-0082(99)00005-2","volume":"59","author":"E Brouillet","year":"1999","unstructured":"Brouillet E, Conde F, Beal MF, Hantraye P (1999) Replicating Huntington\u2019s disease phenotype in experimental animals. Prog Neurobiol 59:427\u2013468","journal-title":"Prog Neurobiol"},{"key":"14_CR35","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1017\/S0317167100032212","volume":"18","author":"AC Ludolph","year":"1991","unstructured":"Ludolph AC, He F, Spencer PS et al (1991) 3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. Can J Neurol Sci 18:492\u2013498","journal-title":"Can J Neurol Sci"},{"key":"14_CR36","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1523\/JNEUROSCI.16-09-03019.1996","volume":"16","author":"S Palfi","year":"1996","unstructured":"Palfi S, Ferrante RJ, Brouillet E et al (1996) Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington\u2019s disease. J Neurosci 16:3019","journal-title":"J Neurosci"},{"key":"14_CR37","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/1531-8257(200005)15:3<524::AID-MDS1016>3.0.CO;2-F","volume":"15","author":"S Palfi","year":"2000","unstructured":"Palfi S, Leventhal L, Goetz CG et al (2000) Delayed onset of progressive dystonia following subacute 3-nitropropionic acid treatment in Cebus apella monkeys. Mov Disord 15:524\u2013530","journal-title":"Mov Disord"},{"key":"14_CR38","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/00019052-199512000-00014","volume":"8","author":"E Brouillet","year":"1995","unstructured":"Brouillet E, Hantraye P (1995) Effects of chronic MPTP and 3-nitropropionic acid in nonhuman primates. Curr Opin Neurol 8:469\u2013473","journal-title":"Curr Opin Neurol"},{"key":"14_CR39","doi-asserted-by":"crossref","first-page":"7105","DOI":"10.1073\/pnas.92.15.7105","volume":"92","author":"E Brouillet","year":"1995","unstructured":"Brouillet E, Hantraye P, Ferrante RJ et al (1995) Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci U S A 92:7105\u20137109","journal-title":"Proc Natl Acad Sci U S A"},{"key":"14_CR40","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1523\/JNEUROSCI.13-10-04181.1993","volume":"13","author":"MF Beal","year":"1993","unstructured":"Beal MF, Brouillet E, Jenkins BG et al (1993) Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 13:4181\u20134192","journal-title":"J Neurosci"},{"key":"14_CR41","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1006\/nbdi.1999.0244","volume":"6","author":"C Dautry","year":"1999","unstructured":"Dautry C, Conde F, Brouillet E et al (1999) Serial 1H-NMR spectroscopy study of metabolic impairment in primates chronically treated with the succinate dehydrogenase inhibitor 3-nitropropionic acid. Neurobiol Dis 6:259\u2013268","journal-title":"Neurobiol Dis"},{"key":"14_CR42","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/00004647-200005000-00005","volume":"20","author":"C Dautry","year":"2000","unstructured":"Dautry C, Vaufrey F, Brouillet E et al (2000) Early N-acetylaspartate depletion is a marker of neuronal dysfunction in rats and primates chronically treated with the mitochondrial toxin 3-nitropropionic acid. J Cereb Blood Flow Metab 20:789\u2013799","journal-title":"J Cereb Blood Flow Metab"},{"key":"14_CR43","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/nature06975","volume":"453","author":"SH Yang","year":"2008","unstructured":"Yang SH, Cheng PH, Banta H et al (2008) Towards a transgenic model of Huntington\u2019s disease in a non-human primate. Nature 453:921\u2013924","journal-title":"Nature"},{"key":"14_CR44","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1471-2202-15-36","volume":"15","author":"AW Chan","year":"2014","unstructured":"Chan AW, Xu Y, Jiang J et\u00a0al (2014) A two years longitudinal study of a transgenic Huntington disease monkey. BMC Neurosci 15:36. https:\/\/doi.org\/10.1186\/1471-2202-15-36","journal-title":"BMC Neurosci"},{"issue":"5","key":"14_CR45","volume":"10","author":"AW Chan","year":"2015","unstructured":"Chan AW, Jiang J, Chen Y et al (2015) Progressive cognitive deficit, motor impairment and striatal pathology in a transgenic Huntington disease monkey model from infancy to adulthood. PLoS One 10(5):e0122335","journal-title":"PLoS One"},{"key":"14_CR46","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1097\/00001756-199406020-00026","volume":"5","author":"E Storey","year":"1994","unstructured":"Storey E, Cipolloni PB, Ferrrante RJ et al (1994) Movement disorder following excitotoxin lesions in primates. Neuroreport 5:1259\u20131261","journal-title":"Neuroreport"},{"key":"14_CR47","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/0014-4886(92)90018-L","volume":"118","author":"P Hantraye","year":"1992","unstructured":"Hantraye P, Leroy-Willig A, Denys A et al (1992) Magnetic resonance imaging to monitor pathology of caudate-putamen after excitotoxin-induced neuronal loss in the nonhuman primate brain. Exp Neurol 118:18\u201323","journal-title":"Exp Neurol"},{"key":"14_CR48","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/brain\/113.2.509","volume":"113","author":"I Kanazawa","year":"1990","unstructured":"Kanazawa I, Kimura M, Murata M et al (1990) choreic movements in the macaque monkey induced by kainic acid lesions of the striatum combined with l-dopapharmacological, biochemical and physiological studies on neural mechanisms. Brain 113:509\u2013535","journal-title":"Brain"},{"key":"14_CR49","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3233\/JHD-130001","volume":"2","author":"M Baxa","year":"2013","unstructured":"Baxa M, Hruska-Plochan M, Juhas S et al (2013) A transgenic minipig model of Huntington\u2019s disease. J Huntingtons Dis 2:47\u201368","journal-title":"J Huntingtons Dis"},{"key":"14_CR50","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3233\/JHD-130050","volume":"2","author":"AJ Morton","year":"2013","unstructured":"Morton AJ, Howland DS (2013) Large genetic animal models of Huntington\u2019s disease. J Huntingtons Dis 2:3\u201319","journal-title":"J Huntingtons Dis"},{"key":"14_CR51","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3233\/JHD-130067","volume":"2","author":"SJ Reid","year":"2013","unstructured":"Reid SJ, Patassini S, Handley RR et al (2013) Further molecular characterisation of the OVT73 transgenic sheep model of Huntington\u2019s disease identifies cortical aggregates. J Huntingtons Dis 2:279\u2013295","journal-title":"J Huntingtons Dis"},{"key":"14_CR52","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1093\/hmg\/ddq063","volume":"19","author":"JC Jacobsen","year":"2010","unstructured":"Jacobsen JC, Bawden CS, Rudiger SR et al (2010) An ovine transgenic Huntington\u2019s disease model. Hum Mol Genet 19:1873\u20131882","journal-title":"Hum Mol Genet"},{"key":"14_CR53","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1093\/hmg\/ddq313","volume":"19","author":"D Yang","year":"2010","unstructured":"Yang D, Wang CE, Zhao B et al (2010) Expression of Huntington\u2019s disease protein results in apoptotic neurons in the brains of cloned transgenic pigs. Hum Mol Genet 19:3983\u20133994","journal-title":"Hum Mol Genet"},{"key":"14_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/srep20681","volume":"6","author":"RR Handley","year":"2016","unstructured":"Handley RR, Reid SJ, Patassini S et al (2016) Metabolic disruption identified in the Huntington\u2019s disease transgenic sheep model. Sci Rep 6:20681. https:\/\/doi.org\/10.1038\/srep20681","journal-title":"Sci Rep"},{"key":"14_CR55","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ymeth.2009.05.007","volume":"49","author":"AW Chan","year":"2009","unstructured":"Chan AW, Yang SH (2009) Generation of transgenic monkeys with human inherited genetic disease. Methods 49:78\u201384","journal-title":"Methods"},{"key":"14_CR56","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1093\/hmg\/ddn175","volume":"17","author":"CE Wang","year":"2008","unstructured":"Wang CE, Tydlacka S, Orr AL et al (2008) Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington\u2019s disease. Hum Mol Genet 17:2738\u20132751","journal-title":"Hum Mol Genet"},{"key":"14_CR57","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1038\/sj.mt.6300185","volume":"15","author":"S Palfi","year":"2007","unstructured":"Palfi S, Brouillet E, Jarraya B et al (2007) Expression of mutated huntingtin fragment in the putamen is sufficient to produce abnormal movement in non-human primates. Mol Ther 15:1444\u20131451","journal-title":"Mol Ther"},{"key":"14_CR58","unstructured":"Aron Badin R, Callander G et al (2013) Characterization of a novel striatal-specific non-human primate model of Huntington\u2019s disease. Movement Disorders. In: 17th International Congress of the Parkinson\u2019s Disease and Movements Disorders, Sydney, Australia, 16\u201320 June 2013, p. 103, abstract 754"},{"key":"14_CR59","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/ajp.22281","volume":"76","author":"KA Phillips","year":"2014","unstructured":"Phillips KA, Bales KL, Capitanio JP et al (2014) Why primate models matter. Am J Primatol 76:801\u2013827","journal-title":"Am J Primatol"},{"key":"14_CR60","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3389\/fnana.2013.00003","volume":"7","author":"L Ventura-Antunes","year":"2013","unstructured":"Ventura-Antunes L, Mota B, Herculano-Houzel S (2013) Different scaling of white matter volume, cortical connectivity, and gyrification across rodent and primate brains. Front Neuroanat 7:3. https:\/\/doi.org\/10.3389\/fnana.2013.00003","journal-title":"Front Neuroanat"},{"key":"14_CR61","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1002\/cne.23431","volume":"521","author":"R Insausti","year":"2013","unstructured":"Insausti R (2013) Comparative neuroanatomical parcellation of the human and nonhuman primate temporal pole. J Comp Neurol 521:4163\u20134176","journal-title":"J Comp Neurol"},{"key":"14_CR62","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.tics.2005.03.005","volume":"9","author":"G Roth","year":"2005","unstructured":"Roth G, Dicke U (2005) Evolution of the brain and intelligence. Trends Cogn Sci 9:250\u2013257","journal-title":"Trends Cogn Sci"},{"key":"14_CR63","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/nn814","volume":"5","author":"K Semendeferi","year":"2002","unstructured":"Semendeferi K, Lu A, Schenker N, Damasio H (2002) Humans and great apes share a large frontal cortex. Nat Neurosci 5:272\u2013276","journal-title":"Nat Neurosci"},{"issue":"2","key":"14_CR64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032322","volume":"7","author":"AM Seelke","year":"2012","unstructured":"Seelke AM, Dooley JC, Krubitzer LA (2012) The emergence of somatotopic maps of the body in S1 in rats: the correspondence between functional and anatomical organization. PLoS One 7(2):e32322","journal-title":"PLoS One"},{"key":"14_CR65","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/978-1-59259-691-1_17","volume-title":"Central nervous system diseases: innovative animal models from lab to clinic","author":"P Hantraye","year":"2000","unstructured":"Hantraye P, Palfi S, Mittoux V et al (2000) Replicating Huntington disease\u2019s phenotype in nonhuman primates. In: Emerich DF, Dean RL, Sanberg PR (eds) Central nervous system diseases: innovative animal models from lab to clinic. Humana Press, Totowa, NJ, pp 333\u2013353"},{"key":"14_CR66","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.neurol.2012.07.002","volume":"168","author":"R Aron Badin","year":"2012","unstructured":"Aron Badin R, Hantraye P (2012) Designing primate models to assess the prodromal phase of Huntington\u2019s disease. Rev Neurol 168:802\u2013805","journal-title":"Rev Neurol"},{"key":"14_CR67","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejphar.2015.03.038","volume":"759","author":"R Aron Badin","year":"2015","unstructured":"Aron Badin R, Vadori M, Cozzi E, Hantraye P (2015) Translational research for Parkinsons disease: the value of pre-clinical primate models. Eur J Pharmacol 759:118\u2013126","journal-title":"Eur J Pharmacol"},{"key":"14_CR68","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/ilar.50.2.107","volume":"50","author":"JH Wolfe","year":"2009","unstructured":"Wolfe JH (2009) Gene therapy in large animal models of human genetic diseases. ILAR J 50:107\u2013111","journal-title":"ILAR J"},{"key":"14_CR69","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0300-483X(03)00043-X","volume":"188","author":"PJ Haley","year":"2003","unstructured":"Haley PJ (2003) Species differences in the structure and function of the immune system. Toxicology 188:49\u201371","journal-title":"Toxicology"},{"key":"14_CR70","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0079-6123(08)62643-6","volume":"82","author":"O Isacson","year":"1990","unstructured":"Isacson O, Hantraye P, Maziere M et al (1990) Apomorphine-induced dyskinesias after excitotoxic caudate-putamen lesions and the effects of neural transplantation in non-human primates. Prog Brain Res 82:523\u2013533","journal-title":"Prog Brain Res"},{"key":"14_CR71","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.nbd.2006.04.014","volume":"23","author":"DF Emerich","year":"2006","unstructured":"Emerich DF, Thanos CG, Goddard M et al (2006) Extensive neuroprotection by choroid plexus transplants in excitotoxin lesioned monkeys. Neurobiol Dis 23:471\u2013480","journal-title":"Neurobiol Dis"},{"key":"14_CR72","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF00248544","volume":"75","author":"O Isacson","year":"1989","unstructured":"Isacson O, Riche D, Hantraye P et al (1989) A primate model of Huntington\u2019s disease: cross-species implantation of striatal precursor cells to the excitotoxically lesioned baboon caudate-putamen. Exp Brain Res 75:213\u2013220","journal-title":"Exp Brain Res"},{"key":"14_CR73","first-page":"25","volume":"7","author":"JT Simmons","year":"1986","unstructured":"Simmons JT, Pastakia B, Chase TN, Shults CW (1986) Magnetic resonance imaging in Huntington disease. AJNR Am J Neuroradiol 7:25\u201328","journal-title":"AJNR Am J Neuroradiol"},{"key":"14_CR74","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/nm0898-963","volume":"4","author":"S Palfi","year":"1998","unstructured":"Palfi S, Conde F, Riche D et al (1998) Fetal striatal allografts reverse cognitive deficits in a primate model of Huntington disease. Nat Med 4:963\u2013966","journal-title":"Nat Med"},{"key":"14_CR75","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1006\/exnr.1994.1005","volume":"125","author":"NE Simmons","year":"1994","unstructured":"Simmons NE, Helm GA, Cail WS et al (1994) Magnetic resonance imaging of neuronal grafts in the primate. Exp Neurol 125:52\u201357","journal-title":"Exp Neurol"},{"key":"14_CR76","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2214\/ajr.158.1.1530764","volume":"158","author":"A Denys","year":"1992","unstructured":"Denys A, Leroy-Willig A, Riche D, Hantraye P (1992) MR appearance of neural grafts in a primate model of Huntington disease. Am J Roentgenol 158:215\u2013216","journal-title":"Am J Roentgenol"},{"key":"14_CR77","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.pneurobio.2007.01.003","volume":"81","author":"C Zuccato","year":"2007","unstructured":"Zuccato C, Cattaneo E (2007) Role of brain-derived neurotrophic factor in Huntington\u2019s disease. Prog Neurobiol 81:294\u2013330","journal-title":"Prog Neurobiol"},{"key":"14_CR78","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1172\/JCI27607","volume":"116","author":"M Borrell-Pages","year":"2006","unstructured":"Borrell-Pages M, Canals JM, Cordelieres FP et al (2006) Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J Clin Invest 116:1410\u20131424","journal-title":"J Clin Invest"},{"key":"14_CR79","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/cne.903490110","volume":"349","author":"DF Emerich","year":"1994","unstructured":"Emerich DF, Winn SR, Harper J et\u00a0al (1994) Implants of polymer-encapsulated human NGF-secreting cells in the nonhuman primate: rescue and sprouting of degenerating cholinergic basal forebrain neurons. J Comp Neurol 349:148\u2013164","journal-title":"J Comp Neurol"},{"key":"14_CR80","doi-asserted-by":"crossref","first-page":"10898","DOI":"10.1073\/pnas.91.23.10898","volume":"91","author":"JH Kordower","year":"1994","unstructured":"Kordower JH, Winn SR, Liu YT et al (1994) The aged monkey basal forebrain: rescue and sprouting of axotomized basal forebrain neurons after grafts of encapsulated cells secreting human nerve growth factor. Proc Natl Acad Sci U S A 91:10898\u201310902","journal-title":"Proc Natl Acad Sci U S A"},{"key":"14_CR81","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/386395a0","volume":"386","author":"DF Emerich","year":"1997","unstructured":"Emerich DF, Winn SR, Hantraye PM et al (1997) Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington\u2019s disease. Nature 386:395\u2013399","journal-title":"Nature"},{"key":"14_CR82","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1089\/10430340050015220","volume":"11","author":"V Mittoux","year":"2000","unstructured":"Mittoux V, Joseph JM, Conde F et al (2000) Restoration of cognitive and motor functions by ciliary neurotrophic factor in a primate model of Huntington\u2019s disease. Hum Gene Ther 11:1177\u20131187","journal-title":"Hum Gene Ther"},{"key":"14_CR83","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1089\/10430340050111377","volume":"11","author":"AC Bachoud-Levi","year":"2000","unstructured":"Bachoud-Levi AC, Deglon N, Nguyen JP et al (2000) Neuroprotective gene therapy for Huntington\u2019s disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF. Hum Gene Ther 11:1723\u20131729","journal-title":"Hum Gene Ther"},{"key":"14_CR84","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1089\/hum.2004.15.968","volume":"15","author":"J Bloch","year":"2004","unstructured":"Bloch J, Bachoud-Levi AC, Deglon N et al (2004) Neuroprotective gene therapy for Huntington\u2019s disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. Hum Gene Ther 15:968\u2013975","journal-title":"Hum Gene Ther"},{"key":"14_CR85","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000360584","volume":"92","author":"ME Emborg","year":"2014","unstructured":"Emborg ME, Hurley SA, Joers V et al (2014) Titer and product affect the distribution of gene expression after intraputaminal convection-enhanced delivery. Stereotact Funct Neurosurg 92:182\u2013194","journal-title":"Stereotact Funct Neurosurg"},{"key":"14_CR86","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/B978-012397632-1\/50010-1","volume-title":"Gene therapy of the central nervous system","author":"J Moirano","year":"2006","unstructured":"Moirano J, Emborg ME (2006) Chapter 9\u00a0\u2013 Nonhuman primate models for testing gene therapy for neurodegenerative disorders A2\u00a0\u2013 Kaplitt, Michael G. In: During MJ (ed) Gene therapy of the central nervous system. Academic Press, Amsterdam, pp 109\u2013119"},{"key":"14_CR87","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.nbd.2011.12.030","volume":"48","author":"S Ramaswamy","year":"2012","unstructured":"Ramaswamy S, Kordower JH (2012) Gene therapy for Huntington\u2019s disease. Neurobiol Dis 48:243\u2013254","journal-title":"Neurobiol Dis"},{"key":"14_CR88","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/B978-0-12-386986-9.00009-0","volume":"102","author":"B Ruozi","year":"2012","unstructured":"Ruozi B, Belletti D, Bondioli L et al (2012) Neurotrophic factors and neurodegenerative diseases: a delivery issue. Int Rev Neurobiol 102:207\u2013247","journal-title":"Int Rev Neurobiol"},{"key":"14_CR89","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1093\/hmg\/ddv442","volume":"25","author":"MS Keiser","year":"2016","unstructured":"Keiser MS, Kordasiewicz HB, McBride JL (2016) Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington\u2019s disease and spinocerebellar ataxia. Hum Mol Genet 25:R53\u2013R64","journal-title":"Hum Mol Genet"},{"key":"14_CR90","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.drudis.2014.09.011","volume":"20","author":"BM Godinho","year":"2015","unstructured":"Godinho BM, Malhotra M, O\u2019Driscoll CM, Cryan JF (2015) Delivering a disease-modifying treatment for Huntington\u2019s disease. Drug Discov Today 20:50\u201364","journal-title":"Drug Discov Today"},{"key":"14_CR91","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.cub.2009.03.030","volume":"19","author":"EL Pfister","year":"2009","unstructured":"Pfister EL, Kennington L, Straubhaar J et\u00a0al (2009) Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington\u2019s disease patients. Curr Biol 19:774\u2013778","journal-title":"Curr Biol"},{"key":"14_CR92","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.nbd.2011.08.023","volume":"48","author":"M Ruiz","year":"2012","unstructured":"Ruiz M, Deglon N (2012) Viral-mediated overexpression of mutant huntingtin to model HD in various species. Neurobiol Dis 48:202\u2013211","journal-title":"Neurobiol Dis"},{"key":"14_CR93","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/mt.2010.106","volume":"18","author":"P Hadaczek","year":"2010","unstructured":"Hadaczek P, Eberling JL, Pivirotto P et al (2010) Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Mol Ther 18:1458\u20131461","journal-title":"Mol Ther"},{"key":"14_CR94","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/ana.21569","volume":"65","author":"V Drouet","year":"2009","unstructured":"Drouet V, Perrin V, Hassig R et al (2009) Sustained effects of nonallele-specific Huntingtin silencing. Ann Neurol 65:276\u2013285","journal-title":"Ann Neurol"},{"key":"14_CR95","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.expneurol.2009.03.004","volume":"217","author":"MS Lombardi","year":"2009","unstructured":"Lombardi MS, Jaspers L, Spronkmans C et al (2009) A majority of Huntington\u2019s disease patients may be treatable by individualized allele-specific RNA interference. Exp Neurol 217:312\u2013319","journal-title":"Exp Neurol"},{"key":"14_CR96","doi-asserted-by":"crossref","first-page":"9634","DOI":"10.1093\/nar\/gkt725","volume":"41","author":"ME Ostergaard","year":"2013","unstructured":"Ostergaard ME, Southwell AL, Kordasiewicz H et al (2013) Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. Nucleic Acids Res 41:9634\u20139650","journal-title":"Nucleic Acids Res"},{"key":"14_CR97","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1038\/mt.2011.219","volume":"19","author":"JL McBride","year":"2011","unstructured":"McBride JL, Pitzer MR, Boudreau R et al (2011) Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington\u2019s disease. Mol Ther 19:2152\u20132162","journal-title":"Mol Ther"},{"key":"14_CR98","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/brain\/awr333","volume":"135","author":"R Grondin","year":"2012","unstructured":"Grondin R, Kaytor MD, Ai Y, Nelson PT et al (2012) Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum. Brain 135:1197\u20131209","journal-title":"Brain"},{"key":"14_CR99","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.expneurol.2011.11.020","volume":"233","author":"DK Stiles","year":"2012","unstructured":"Stiles DK, Zhang Z, Ge P et al (2012) Widespread suppression of huntingtin with convection-enhanced delivery of siRNA. Exp Neurol 233:463\u2013471","journal-title":"Exp Neurol"},{"key":"14_CR100","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.20","volume":"4","author":"R Grondin","year":"2015","unstructured":"Grondin R, Ge P, Chen Q et al (2015) Onset time and durability of huntingtin suppression in rhesus putamen after direct infusion of antihuntingtin siRNA. Mol Ther Nucleic Acids 4:e245","journal-title":"Mol Ther Nucleic Acids"},{"key":"14_CR101","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","volume":"74","author":"HB Kordasiewicz","year":"2012","unstructured":"Kordasiewicz HB, Stanek LM, Wancewicz EV et al (2012) Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of huntingtin synthesis. Neuron 74:1031\u20131044","journal-title":"Neuron"},{"key":"14_CR102","volume":"10","author":"ME Downs","year":"2015","unstructured":"Downs ME, Buch A, Sierra C et al (2015) Correction: Long-term safety of repeated blood-brain barrier opening via focused ultrasound with microbubbles in non-human primates performing a cognitive task. PLoS One 10:e0130860","journal-title":"PLoS One"},{"key":"14_CR103","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.gene.2014.11.022","volume":"556","author":"A Kumar","year":"2015","unstructured":"Kumar A, Kumar Singh S, Kumar V et al (2015) Huntington\u2019s disease: an update of therapeutic strategies. Gene 556:91\u201397","journal-title":"Gene"},{"key":"14_CR104","doi-asserted-by":"crossref","first-page":"18219","DOI":"10.1073\/pnas.1421313111","volume":"111","author":"L Ripaud","year":"2014","unstructured":"Ripaud L, Chumakova V, Antonin M et al (2014) Overexpression of Q-rich prion-like proteins suppresses polyQ cytotoxicity and alters the polyQ interactome. Proc Natl Acad Sci U S A 111:18219\u201318224","journal-title":"Proc Natl Acad Sci U S A"},{"key":"14_CR105","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1093\/hmg\/ddq212","volume":"19","author":"M Faideau","year":"2010","unstructured":"Faideau M, Kim J, Cormier K et al (2010) In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington\u2019s disease subjects. Hum Mol Genet 19:3053\u20133067","journal-title":"Hum Mol Genet"},{"key":"14_CR106","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.it.2015.04.007","volume":"36","author":"A Crotti","year":"2015","unstructured":"Crotti A, Glass CK (2015) The choreography of neuroinflammation in Huntington\u2019s disease. Trends Immunol 36:364\u2013373","journal-title":"Trends Immunol"},{"key":"14_CR107","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11758","volume":"7","author":"A Benraiss","year":"2016","unstructured":"Benraiss A, Wang S, Herrlinger S et al (2016) Human glia can both induce and rescue aspects of disease phenotype in Huntington disease. Nat Commun 7:11758","journal-title":"Nat Commun"},{"key":"14_CR108","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12035-008-8043-y","volume":"38","author":"C Escartin","year":"2008","unstructured":"Escartin C, Bonvento G (2008) Targeted activation of astrocytes: a potential neuroprotective strategy. Mol Neurobiol 38:231\u2013241","journal-title":"Mol Neurobiol"}],"container-title":["Methods in Molecular Biology","Huntington\u2019s Disease"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-7825-0_14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T17:52:19Z","timestamp":1604339539000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-7825-0_14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9781493978243","9781493978250"],"references-count":108,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-7825-0_14","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/978-1-4939-7825-0","asserted-by":"object"}]},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}